Crossamerica Partners Lp SEC Filings

CrossAmerica Partners LP (CAPL) – Form 4 insider filing.

Director and 10% owner Joseph V. Topper Jr. converted vested phantom units into 3,419 common units on 07/23/2025 (Transaction Code M). After the transaction, he directly owns 93,404 common units. The phantom units were economically equivalent to one common unit each and vested on the same date; they were settled at the issuer’s discretion. No derivative securities remain outstanding and no sales or open-market purchases were reported.

The filing shows a routine increase in insider ownership with no other material corporate events disclosed.

On 07/21/2025, Steven H. Stein, EVP & Chief Medical Officer of Incyte Corp. (INCY), filed a Form 4 reporting the sale of 3,706 common shares at $67.94 per share (≈ $252 k gross proceeds). After the transaction, Stein still beneficially owns 102,886 shares, a figure that includes 100,327 unvested restricted stock units and earned performance shares disclosed in footnote 1. No derivative securities were acquired or disposed of in this filing and no additional transactions were reported.

The filing represents a routine insider sale amounting to roughly 3.6 % of Stein’s post-transaction holding. There is no indication of option exercise, stock-for-tax withholding, or special circumstances; therefore, investment impact appears limited.

Form 4 filed for CrossAmerica Partners LP (CAPL) discloses that director Mickey Kim acquired 3,419 common units on 23 Jul 2025. The units were received through the vesting and mandatory conversion of an equal number of phantom units, coded “M,” indicating no open-market activity. After the transaction, Kim directly owns 30,844 common units and holds no remaining phantom units related to this award.

The filing represents a routine equity-incentive settlement that modestly raises insider ownership and further aligns the director’s economic interest with other unitholders. No sales, cash purchases, or additional derivative grants were reported, and the document contains no financial performance data or forward-looking statements.

CrossAmerica Partners LP (CAPL) Form 4: On 07/23/2025, director Justin A. Gannon received 3,154 phantom units (economically equivalent to common units) at a cost basis of $0, coded “A” (grant). The award raises his derivative position to 36,528 phantom units, all held directly.

The phantom units carry distribution-equivalent rights and will vest in a single installment on the first anniversary of the grant, contingent on continued board service. Upon vesting, CAPL may settle the units in cash or common units at its discretion. No common units were sold or otherwise disposed of, and the filing reflects routine director compensation rather than open-market activity; therefore, immediate dilution and cash impact are negligible.

On 23 July 2025, CrossAmerica Partners LP (CAPL) director Justin A. Gannon converted 3,419 phantom units (Code M) into the same number of common units. No units were sold; the transaction strictly reflects vesting of equity-based compensation. Following the conversion, Gannon’s direct ownership increased to 36,528 common units. The phantom units carried no stated exercise price and, after conversion, the derivative balance fell to zero.

Because the acquisition represents a routine incentive-equity vesting rather than an open-market purchase, it is generally viewed as informational rather than materially price-sensitive. Still, the transaction modestly aligns insider and unitholder interests by increasing the director’s direct equity stake.

Columbus McKinnon Corp. (CMCO) – Form 4 filing dated 22-Jul-2025

Independent director Aziz S. Aghili reported the grant of 8,553 deferred stock units (DSUs) on 21-Jul-2025 under the company’s 2016 Long-Term Incentive Plan. Each DSU represents one CMCO common share and carries no exercise price. The grant lifts the director’s indirect holdings to 19,554.0454 DSUs, while his direct ownership of common stock remains at 11,993 shares. The DSUs will be settled in stock upon specified future dates: 4,220.7283 on 31-Dec-2025, 3,226.4392 on 01-Jun-2026, 3,553.8779 on 01-Jan-2027, and the remaining 8,553 after board service ends.

No shares were sold and no cash transactions occurred; therefore, the filing primarily reflects routine equity-based compensation aimed at aligning director incentives with shareholder interests. The transaction is non-dilutive and immaterial to CMCO’s share count and does not alter control or insider selling trends.

CrossAmerica Partners LP (CAPL) – Form 4 insider filing

Director and 10% owner John B. Reilly III reported the conversion of 3,419 phantom units into an equal number of common units on 07/23/2025 (Transaction Code M). Following the conversion, Reilly’s direct holdings rose to 33,467 common units; all corresponding phantom units were extinguished, leaving 0 derivative units outstanding. Each phantom unit was economically equivalent to one common unit and vested on the same date.

No sales were disclosed, and there is no price information provided. The filing reflects a modest increase in the insider’s equity stake and maintains his status as both a Director and 10% owner.

On 23 Jul 2025, CrossAmerica Partners LP (CAPL) filed a Form 4 indicating that director Thomas E. Kelso received an equity-linked award of 3,154 phantom units. Each phantom unit equals one common unit and carries distribution-equivalent rights. The grant was reported under transaction code “A” at $0, raising Kelso’s derivative holdings to 9,144 phantom units.

The phantom units vest in a single installment on the first anniversary of the grant, contingent on continuous board service, and may be settled in either cash or common units at the issuer’s discretion. No open-market trades of CAPL common units were disclosed, and ownership remains direct. The filing reflects routine director compensation and has no immediate impact on the partnership’s capital structure or liquidity.

On 23 Jul 2025 CrossAmerica Partners LP (CAPL) director Kenneth G. Valosky filed Form 4 reporting the grant of 3,154 phantom units, each economically equivalent to one common unit. The award was received at $0 cost as part of the partnership’s director compensation program.

The phantom units vest in a single installment on the first anniversary of the grant, provided Valosky remains on the board, and will be settled in cash or common units at the issuer’s discretion. After the transaction, his derivative holdings total 23,804 phantom units; no acquisitions or dispositions of actual common units were disclosed.

This is a routine, incentive-alignment grant that marginally increases insider exposure but is unlikely to have a material near-term market impact.